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DNA technology created a novel opportunity for man-
agement of several debilitating and life threatening dis-
eases. However, these medicines are very expensive and
therefore not affordable for many patients especially
those living in low resourced countries. Biopharmaceuti-
cals mostly have a high unit cost and often prescribed
for chronic medical conditions with possibility of long-
term use. Therefore, they will impose a burden on either
national health care systems or patients’ out of pocket. It
is estimated that the average daily treatment of a patient
with branded biopharmaceuticals will cost at least 22
times of those for small molecule medicines [1]. Bio-
pharmaceuticals are medicines produced from living
organisms via genetic manipulation. Although use of liv-
ing organisms for production of vaccines has a long his-
tory, the first DNA recombinant medicine for human
use, human insulin, was approved in the USA in 1982.
However, introduction of other biopharmaceuticals in-
cluding monoclonal antibodies into market later on
experienced a much faster pace. Biopharmaceuticals are
large and complex molecules which their active sub-
stances are mostly polypeptides, glycoproteins, proteins,
and nucleic acids. Therefore, it is practically impossible
to manufacture an “identical” copy for these molecules.
Blood coagulating factors, erythropoietins, gonadotro-
phins, granulocyte colony stimulating factor (GCSF),
human growth hormones (GH), interferons (INF), inter-
leukins and monoclonal antibodies are among the
most important marketed biopharmaceuticals in past
decades [2].Correspondence: majidcheraghali@gmail.com
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reproduction in any medium, provided the orDespite complexity of their molecules, biopharma-
ceuticals are very well characterized both for their clin-
ical use and production methods. Biopharmaceuticals
are also very sensitive to their production procedures.
When the manufacturing process is modified by scaling
up or transferring it to alternative facilities, new pro-
ducts might show modified specifications. Even though
these manufacturing changes are tightly regulated most
of the time they still will cause observable changes in
the final product. However, all of these products will
be marketed under one single brand name indicating
that regulators consider these changes in the range of
“highly similar” products. The fact that their adminis-
tration provides expected clinical outcomes also con-
firm their comparability.
“Biosimilars” are biopharmaceuticals which are manu-
factured by non originator pharmaceutical companies
following expiration of patent period. According to cur-
rent guidelines and regulations for granting marketing
authorization “similarity” should be proven between biosi-
milar and its corresponding originator biopharmaceutical.
Biopharmaceuticals have a very fast growing market.
It is reported that 32% of products in development
pipeline and 7.5% of marketed medicines are biophar-
maceuticals which account for around 10% of pharma-
ceutical expenditure [3]. It is forecasted that by 2020,
biopharmaceuticals will sell around US$23 billion in
the EU and US$29 billion in the USA and of course
all of this market could be challenged by biosimilars
[3]. The biopharmaceutical market has expanded dras-
tically in the past two decades. Although most of these
medicines enjoyed exclusivity in the market due to
their patent; recent years have witnessed expiration of
their patent.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Since in coming years more and more biopharmaceuticals
will lose their patent protection, many pharmaceutical
companies including biotechnology industry and generics
manufacturers, as well as regulatory agencies, are becom-
ing increasingly interested in biosimilars [4].
However, contrary to the small molecule medicines
generics replication of biopharmaceuticals is somehow
a complex and controversy issue. Biopharmaceuticals
usually have large and complex molecular structures
of protein nature which in many cases replication of
these systems in order to produce “identical and similar”
molecules are very difficult. Most of the times, small
changes in the structure of the final molecule might cre-
ate different safety and efficacy profile. Therefore changes
in the manufacturing process can cause complications for
potential biosimilars. New molecules could cause severe
immunogenicity reactions. That is why evaluation of bio-
similars becomes a serious challenge for both the scien-
tific community and regulatory agencies [5].
Despite presence of biosimilars in some markets since
years ago several highly regulated markets such as USA,
until recently did not have any regulations for registra-
tion of these medicines. In 2004, European Medicine
Agency (EMA) was the first well established regulatory
authority to develop a comprehensive guideline for
dealing with biosimilars [6]. The main concept of “bio-
similarity” in this guideline relies on a head to head
demonstration of similarity of the new medicine from
both physicochemical and biological activity point of
view to a reference originator biopharmaceutical. Since
then EMA has authorized more than 14 biosimilars for
marketing in EU. Until 2010, the FDA lacked the legal
authority to approve biosimilar medicines similar to
what is already happening in EU. However, with new
reform of health care system in USA, FDA has now
the authority to review and approve “highly similar”
biosimilar medicines.
WHO has published its first guideline for evaluation
of biosimilars in 2010 [7,8]. This guideline also relies on
a head to head demonstration of biosimilarity of a biosi-
milar with a registered biopharmaceutical. This head to
head comparison involves both quality non-clinical and
clinical aspects of the products. Clinical study should de-
sign in a way that would be able to demonstrate compar-
able safety and efficacy between biosimilar and reference
biopharmaceutical.
However, there are some experts who believe that per-
forming head to head preclinical and clinical trials be-
tween brand and biosimilar may not be necessary and in
fact this might deprive patients of cost effectiveness
treatment and compromise patients’ affordability [9].
Some other researchers even believe that the clinical
trials required by EMA to compare biosimilars and theircorresponding originator product may even be a barrier
for the development of future, more advanced biophar-
maceuticals [10].
Highly regulated markets such as USA and EU have
specific requirements for biosimilars regarding compara-
tive studies proofing similar safety, efficacy, purity and
potency for biosimilars and their brand comparator.
Therefore developing biosimilars in these markets re-
quire substantial investments estimated in the range of
75–250 million USD [10]. However, this might not be
the case for marketing of biosimilars in less regulated
markets. Therefore biosimilars in these markets could
have different definitions. Although such products might
have acceptable safety and efficacy profile based on local
requirements they are not “biosimilars” as they have
been defined by FDA, EMA or even WHO guidelines.
As an example according to a published report, among
several recombinant erythropoietins manufactured in
Asia none was comparable with the originator product
from structural point of view [11]. However, according
to the similar methodology, biosimilar erythropoietin
marketed in EU was identical with originator [12].
Therefore there is a very low chance for biosimilars
developed outside of EU or USA to be approved by FDA
or EMA as biosimilar medicine.
Although in many cases, following any change made
in production process of biopharmaceuticals originators
should ask for regulatory permission for marketing of
their products, authorities even in EU or USA do not
ask for new preclinical or clinical data in these cases. If
the product fall within the variability of the originator
molecule after manufacturing change then the new
product would be considered “highly similar” to the ori-
ginator molecule.
Surprisingly, FDA has recently used a non-clinical
based approach for granting marketing authorization to
the biosimilars. In 2010, FDA approved a generic Enoxa-
parin as a fully substitutable generic to Sanofi-Aventis
Lovenox (Enoxaparin). In reviewing the Enoxaparin file,
FDA used five criteria to establish “sameness” for these
two products. None of them were pre-clinical or clinical
data. In fact FDA used the analytical characterization to
grant similarity status to the generic Enoxaparin [10].
Cost impact of biosimilars
Although global sale of biopharmaceuticals in 2009 was
over 93 billion USD, their sales expected to grow at least
as twice as fast compared to those of small molecules. It
is estimated that by 2016, ten of the 20 top selling
medicines will be biological medicines. It is also esti-
mated that share of off patent products in biopharma-
ceutical market will exceed 40% of global sale in 2015
[3,13]. This optimistic market forecast for biopharmaceu-
ticals has convinced both multinational and national
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on developing these medicines.
Cost containment pressures in healthcare systems
could be considered as a key driver for the biosimilars
market. Current biopharmaceuticals on the market are
too expensive that even a modest price reduction
through marketing of biosimilars could attract attention
of policy makers in health sector. Marketing of biosimi-
lars not only will facilitate access to these highly effective
medicines, but also reported to be cost effective treat-
ments and could create substantial saving for national
health sectors [13]. It has been reported that newly
established biosimilar medicines already generated
around 1.4 billion Euros saving per year for European
healthcare systems [14]. Obviously this saving might be
used for next generation of originator medicines. There-
fore, biosimilars could also have a major impact on af-
fordability of biopharmaceuticals in all markets and
especially in low resourced countries.
Biosimilars market is so lucrative that both multi-
national pharmaceutical companies and local industries
have rushed for manufacturing such medicines. For ex-
ample in 2011 Sandoz announced that it was starting a
phase II clinical trial for a biosimilar version of
Rituximab. Sandoz has already several biosimilars either
on the market or at various stages of development [15].
In other countries, even governments decided to sup-
port manufacturing of the biosimilars. South Korean
government is actively promoting the biosimilars indus-
try in order to make South Korea a market leader in
this field. The government is providing both financial
and institutional support and is aiming to take a 22%
share of the global market by 2020 [16]. Some Indian
and Chinese companies also decided to invest on biosi-
milars. Their main aim is to manufacture biosimilars
which are much cheaper than those produced by other
companies. Cipla and a Chinese partner, BioMab,
investing 124 million Euros to build plants in India and
China to produce biopharmaceuticals.
Biopharmaceuticals in Iran market
Iran national pharmaceutical industry has a more than
half century history. However, these are mostly generic
based companies which produce small molecule medi-
cines. Since decade ago some newly established science
based Iranian pharmaceutical companies started projects
on developing biopharmaceutical. Iran government has
also allocated substantial resources for supporting local
pharmaceutical companies to manufacture biopharma-
ceuticals. This include both financial and administration
supports. Pharmaceutical companies in countries such
as Iran do not have access to the production proce-
dures of originators including cell type, fermentation
and purification procedures. Therefore they could notclaim “similarity” for their products to those of origin-
ator brand.
Despite the fact that biopharmaceuticals which were
produced by local Iranian industry in past decade in-
cluding INFs, GCSF and GH have received marketing
authorization for local market, none of them received
comprehensive evaluation according to those of inter-
nationally recognized guidelines for biosimilars. Registra-
tion of these biopharmaceuticals has mainly followed
registration path for “biogeneric” medicines and their
application for marketing authorization handled based
on case by case. Since 2003 about 6 biopharmaceuticals
produced as non originator copy have been registered by
Iran national authority. These include erythropoietins,
INFs, GH and GCSF. Another 16 are in pipeline and
expected to reach Iran market with similar approach in
coming years [17].
Iran has a fairly well established national Adverse Drug
Reaction (ADR) reporting system and so far no serious
or unexpected ADRs related to administration of these
locally manufactured biopharmaceuticals have been
reported to the national health authorities. This could be
considered as an indication of safety of these locally
manufactured biopharmaceuticals.
However, based on a national guideline which was
mainly adapted from WHO guideline, since 2006 per-
forming a double blind controlled clinical trial with
small sample size for locally manufactured biopharma-
ceuticals becomes obligatory. Although Iran national
regulatory authority (NRA) has tried to use WHO guide-
line on biosimilars for granting marketing authorization,
there are clearly differences between WHO guideline
and current Iran national guideline for registration of lo-
cally produced biopharmaceuticals [17].
Iran is not a member of World Trade Organization
(WTO) and therefore local pharmaceutical industries
have the privilege not to respect internationally recog-
nized intellectual property rights and patents regarding
medicines including biopharmaceuticals. Although there
are national laws and regulations for protection of
patents and brands registered by Iranian companies in-
side the Iran territory, these regulations do not apply for
foreign companies and their products registered outside
of Iran. Therefore the tension between intellectual prop-
erty rights and competition law, which can be seen in
many industries, is not a valid concern for local pharma-
ceutical industry in Iran. Although Iran has applied for
WTO membership, due to current local and inter-
national political situations such membership will not
happen in near future. Therefore it cannot be considered
as an eminent concern for manufacturing of patent bio-
pharmaceuticals by local industry.
Providing that local pharmaceutical companies could have
access to the production procedures of biopharmaceuticals,
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patent biopharmaceuticals. Although conventional local
pharmaceutical companies do not have the capacity to
provide high tech biopharmaceuticals [18-20], newly
established science based Iranian pharmaceutical com-
panies have shown the ability to access to the production
procedures of biopharmaceuticals and actually manufac-
ture such medicines.Conclusion
Health care expenditure has been raised drastically in re-
cent years. Costs attributed to the medicines and espe-
cially biopharmaceuticals consumes substantial share of
healthcare budget. Therefore health services providers
including healthcare authorities or insurance companies
are struggling to find ways to reduce the healthcare
budget. Although biosimilars proved to be a cost effect-
ive intervention for providing effective treatment for
patients, regulatory approaches proposed for marketing
of these medicines by organizations such as EMA, FDA
or even WHO may not suite needs of Iran market.
Iran authorities should keep in mind that WHO biosi-
milar guideline is mainly adapted from EMA guideline
and there is no proof that this guideline is in fact in line
with the needs and interests of national pharmaceutical
markets in low resourced countries such as Iran. Iran
national pharmacovigilance center proved to be an effi-
cient center. Therefore in order to make a balance be-
tween regulation of biopharmaceuticals manufactured by
local industry and affordability of these medicines, Iran
NRA should use this capacity as a tool in regulation of
locally manufactured biopharmaceuticals. Author
believes that Iran NRA should accept pharmacokinetic
and pharmacodynamic equivalence between the origin-
ator and locally manufactured biopharmaceuticals as a
measure of clinical comparability. However, biopharma-
ceuticals have varying potentials for immunogenicity
that could be changed based on number of factors, in-
cluding manufacturing processes. Therefore, it is essen-
tial that rigorous pharmacovigilance approach should be
maintained in order to exclude possible immunogenicity
or other important adverse events related to the locally
produced biopharmaceuticals.
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